LAUSR

ABSTRACT Background We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC). Methods Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR). Results Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81–0.98), HR = 0.84 (95% CI, 0.75–0.93), OR = 2.77 (95% CI, 2.01–3.80), and OR = 4.64 (95% CI, 2.40–8.99), respectively. The adverse events of HAIC were lower than TACE. Conclusion Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.